

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
628 North Fourth Street
Baton Rouge, LA
Bienville Building, Room #118
October 27, 2023
9:00 AM**

- I. Call to Order.....Ben Orlando
- II. Parliamentary Business Ben Orlando
 - A. Introduction of Members/Roll Call
 - B. Attendance/Additional Meetings
 - C. Approval of November 4, 2022 Meeting Minutes
 - D. Approval of May 5, 2023 Unofficial Virtual Meeting Minutes
- III. Reports.....Melwyn Wendt
 - A. PDL Reflecting Spring 2023 Recommendations
- IV. New Business.....Hind Douiki
 - A. Explanation of TOP\$, Monographs and Cost Sheets
 - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
 - 1. Alzheimer’s Agents
 - 2. Anthelmintics
 - 3. Anti-Allergens, Oral
 - 4. Anticonvulsants
 - 5. Antidepressants, Other
 - 6. Antidepressants, SSRIs
 - 7. Antihistamines, Minimally Sedating
 - 8. Antihypertensives, Sympatholytics
 - 9. Antihyperuricemics
 - 10. Antiparkinson’s Agents
 - 11. Antipsoriatics, Oral
 - 12. Antipsoriatics, Topical
 - 13. Antipsychotics
 - 14. Anxiolytics
 - 15. Bile Salts
 - 16. Botulinum Toxins
 - 17. Bronchodilators, Beta Agonist
 - 18. Colony Stimulating Factors
 - 19. COPD Agents
 - 20. Cytokine and CAM Antagonists
 - 21. Emollients
 - 22. Enzyme Replacement, Gauchers Disease
 - 23. Epinephrine, Self-Injected
 - 24. Erythropoiesis Stimulating Proteins
 - 25. Glucocorticoids, Inhaled

26. Glucocorticoids, Oral
27. Hemophilia Treatment
28. Histamine II Receptor Blocker
29. Idiopathic Pulmonary Fibrosis
30. Immune Globulins
31. Immunomodulators, Asthma
32. Immunomodulators, Atopic Dermatitis
33. Immunomodulators, Lupus
34. Immunomodulators, Topical
35. Immunosuppressives, Oral
36. Intranasal Rhinitis Agents
37. Leukotriene Modifiers
38. Methotrexate
39. Movement Disorders
40. Neuropathic Pain
41. NSAIDs
42. Oncology Oral – Breast
43. Oncology Oral – Hematologic
44. Oncology Oral - Lung
45. Oncology Oral – Other
46. Oncology Oral – Prostate
47. Oncology Oral – Renal Cell
48. Oncology Oral - Skin
49. Ophthalmic Antibiotics
50. Ophthalmic, Antibiotic-Steroid Combinations
51. Ophthalmics for Allergic Conjunctivitis
52. Ophthalmics, Anti-Inflammatories
53. Ophthalmics, Anti-Inflammatory/ Immunomodulator
54. Ophthalmics, Cystinosis
55. Ophthalmics, Glaucoma Agents
56. Otic Antibiotics
57. Otic Anti-Infectives & Anesthetics
58. Progestational Agents
59. Sedative Hypnotics
60. Sickle Cell Anemia Treatments
61. Smoking Cessation
62. Spinal Muscular Atrophy - New
63. Steroids, Topical High
64. Steroids, Topical Low
65. Steroids, Topical Medium
66. Steroids, Topical Very High
67. Stimulants and Related Agents
68. Thrombopoiesis Stimulating Proteins
69. Urea Cycle Disorders, Oral

70. Acne Agents - ZMA Clear Cleanser
71. Antibiotics, GI - VOWST™
72. Antimigraine Agents, Other - Zavzpret™
73. Cystic Fibrosis, Oral - TRIKAFTA® Packet
74. Growth Hormone - Sogroya®
75. Hypoglycemics, Insulin and Related Agents – Rezvoglar™ Kwikpen
76. Hypoglycemics, SGLT2 - Inpefa™
77. Lipotropics, Statins – Atorvaliq®
78. Multiple Sclerosis – Briumvi®
79. Opiate Dependence Treatments - Brixadi® Monthly and Brixadi® Weekly
80. PAH Agents, Oral and Inhaled - Liqrev® Suspension

VI. Other Business

VII. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

VIII. Next Proposed Meeting Dates – April 24, 2024, or April 26, 2024 or May 1, 2024 or May 3, 2024

IX. Public Testimony